Background {#Sec1}
==========

Postanesthetic shivering is a frequent complication of anesthesia, perhaps even aggravating pain. It is characterized by involuntary movement that may affect one or more muscle groups and is a very unpleasant and physiologically stressful experience. Postanesthetic shivering can interfere with electrocardiography (ECG) and oxygen saturation (SpO2) monitoring \[[@CR1]\]. More importantly, it can increase oxygen consumption combined with minute ventilation and carbon dioxide production. Moreover, it is believed that postanesthetic shivering can increase mortality in the elderly and patients with coronary artery disease \[[@CR2]\].

The aetiology of shivering is not sufficiently understood. Thermoregulatory and non-thermoregulatory factors may contribute to postoperative shivering including exposure to cold weather, inadequate pain control, and opioid withdrawal \[[@CR3], [@CR4]\]. The gold standard for treatment and prevention has not yet been defined. A variety of pharmacological treatments and methods to reduce postoperative shivering have been used including meperidine, alfentanil, tramadol, magnesium sulfate, ondansetron, dolasetron, and dexmedetomidine \[[@CR5]--[@CR9]\]. Ketamine has also been used as an anti-shivering drug. It is a non-competitive N-methy-D-aspartate (NMDA) receptor antagonist; it may prevent postanesthetic shivering by decreasing core-to-peripheral heat distribution. Although many published literatures have investigated the potential effects of ketamine for prevention of postanesthetic shivering, there is no consensus regarding the appropriateness of this drug. Thus, an evidence-based understanding of the benefits and risks of ketamine would identify its rational and optimal use. We conducted the meta-analysis to assess the efficacy and safety of ketamine for the prevention of shivering in patients undergoing various surgical procedures.

Methods {#Sec2}
=======

This meta-analysis was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines.

Search strategy {#Sec3}
---------------

Two authors (Y.Z., A.M.) independently searched MEDLINE (2000 to March 2018), EMBASE (2000--2018), and the Cochrane Central Register of Controlled Trails (March 2018) with no language restrictions. By reviewing the references of the eligible articles, we identified additional studies relevant to our meta-analysis. The following search-term strategy was used:

1\) shivering; 2) tremor; 3) shake; 4) hypothermia; 5) anesthesia; 6) postanesthetic; 7) postoperative; 8) surgery; 9) ketamine; 10) 1 or 2 or 3 or 4; 11) 5 or 6 or 7 or 8; 12) 9 and 10 and 11.

Criteria for considering studies for this review {#Sec4}
------------------------------------------------

The selection criteria were pre-established. Inclusion criteria were: (1) controlled clinical trial; (2) prophylactic use of ketamine compared with a placebo or other pharmacological interventions; (3) reported the incidence of postoperative shivering. Trials were not considered for the following reasons: (1) other anti-shivering drugs were also administrated during the anesthetic induction or maintenance period besides ketamine; (2) data from abstracts, letters, or reviews. We included any participants undergoing operative procedures with general or spinal anesthesia. The following outcomes were measured: (1) incidence of postanesthetic shivering; (2) sedation score; (3) incidence of other side effects.

Data collection and analysis {#Sec5}
----------------------------

Two review authors (Y.Z., A.M.) independently screened all the titles and abstracts of the studies during the initial search to identify the included studies. After removing the duplicates, potentially relevant studies were retrieved in full-text version for the further assessment. We resolved any disagreement by discussion with another author (G. H. L) of our group.

Data extraction was conducted by two authors (Y.Z., A.M.) independently using the data collection form established previously. The following data were collected from each study: primary author, publication year, anesthetic methods, demographic characteristics of participants, surgery types, comparisons, and other non-pharmacological warming methods. We recorded the number of patients experiencing shivering in each group for dichotomous data.

We used the Review Manager software of the Cochrane Collaboration (RevMan 5.2) to perform the quantitative analysis. The results of dichotomous data are expressed as odds ratio (OR) and 95% confidence intervals (CIs). Heterogeneity testing was performed with Z score and X^2^ statistical analysis; *P* \< 0.1 was considered to indicate heterogeneity. The fixed effect model or the random effect model were applied according to the heterogeneity of the study. A fixed effect model was used when I^2^ \< 50%. We reported the results of included studies when the pooled analysis was not appropriate. Sensitivity and subgroup analysis were performed to explore the reason for the heterogeneity. Subgroup analysis was conducted based on the anesthetic methods, various doses of ketamine used, and the types of surgery. Publication bias was evaluated by Begg's test using Stata 13.1 software (Stata, College Station, TX, USA).

Results {#Sec6}
=======

Search results and characteristics of the studies {#Sec7}
-------------------------------------------------

The flow chart (Fig. [1](#Fig1){ref-type="fig"}) shows the process by which the selected studies were searched. A total of 361 potential articles were identified. We reviewed 30 full-text articles, after screening the titles and the abstracts. A total of 16 \[[@CR10]--[@CR25]\] studies including 1485 patients met our selection criteria and were included in the analysis (Table [1](#Tab1){ref-type="table"}). Fig. 1Flow diagram showing the process of studies selection Table 1Summary of Characteristics of Included StudiesStudy IDParticipantsSurgery TypesAnesthesia MethodsComparisonNon-pharmacological Warming MethodsControl GroupIntervention GroupSagir 2007160 patients 18-65 yrurological surgerySAC(40): saline ivK(40):ketamine 0.5 mg/kg iv;G(40):granisetron 3 mg,iv;KG(40) ketamine 0.25/kg + granisetron 1.5 mg ivAll patients were covered with drapes and a cotton blanket. Fluids were preheated to 37^o^cHonarmand 2008120 patients 18-60 yrorthopaedic surgerySAC(30) saline iv; K(30) ketamine 0.5 mg/kg iv;M(30) midazolam 75 μg/kg iv; KM(30) ketamine 0. 25 mg/kg + midazolam 37.5 μg/kg ivFluids were preheated to 37^o^cZahra 2008120 patients 5-12 yrtonsillectomy surgeryGAC(40):salineK(40):ketamine 1 mg/kg;P(40):pethidine 0.5 mg/kgNone.Han 201093 patients 51-78 yrtransurethral resection of the prostateSAC(31): epidural 0.75% ropivacaineK1(32): epdural ketamine 0.2 mg/kg + 0.75%ropivacaine; K2(30): epidural ketamine 0.4 mg/kg + 0.75%ropivacaineNoneShakya 2010120 patientsLower abdominal surgerySAC(40):saline ivK(40): ketamine 0.25 mg/kg iv;O(40):ondansetron 4 mg ivPatients were covered with standard single blanketAyatollahi 2011120 patients 20-50 yrendoscopic sinus surgeryGAC(30): saline ivK1(30): 0.3 mg/kg iv; K2(30): 0.5 mg/kg iv; M(30): meperidine 0.4 mg/kg ivPatients were covered with a cotton blanketNorouzi 2011120 patients 18-65 yrelective orthopedic surgeryGAC(30):saline ivK1(30):ketamine 0.125 mg/kg iv;K2(30):ketamine 0.25 mg/kg iv;K3(30):ketamine 0.5 mg/kg ivNoneWason 2012200 patients 18-65 yrower abdominal or lower limb surgerySAC(50):saline ivK(50):ketamine 0.5 mg/kg iv;C(50):clonidine 75mcg;T(50):tramadol 0.5 mg/kg ivFluids were preheated to 37^o^cZavareh 2012135 patients 18--70 yrelective surgeryGAK(45):ketamine 0.5 mg/kg iv;P(45):pethidine 0.5 mg/kg;D(45):dexamethasone,0.6 mg/kgNoneAbdelhalim 2014120 patients 18-45 yrENT surgeryGAC(30): saline ivO(30): ondansetron 8 mg iv; K(30): ketamine 0.5 mg/kg iv; OK(30) ondansetron 8 mg + ketamine 0.25 mg/kg ivNonePetskul 2016183 patients 18-65 yrorthopedic surgeryGAC(92):saline ivK(91):ketamine 0.25 mg/kg ivAll patients were warmed by air force warmerMohtadi 2016117 patients 18-40 yrcesarean sectionSAC(39):saline ivK(39):ketamine 0.25 mg/kg,iv;O(39):ondansetron 4 mg,ivNoneHasannasab 2016120 patients 20-45 yrgynecologic surgeryGAK(40): ketamine 0.25 mg/kg iv;M(40): meperidine 20 mg iv; D(40): doxapram 0.25 mg/kg ivPatients were covered with a standard blanketLakhe 2017120 patients 18--65 yearsgynecological and orthopedic surgerySAC(30):saline,ivT(30):tramadol 0.5 mg/kg iv O(30):ondansetron 4 mg,iv;K(30):ketamine 0.25 mg/kg ivPatients were covered with drapesLema 2017123 patients 18-39 yrcesarean sectionSAC(41):saline ivK(41):ketamine 0.2 mg/kg iv;T(41): tramadol 0.5 mg/kg ivPatients were covered with drapesAbbreviations: *yr* years; *GA* general anesthesia; *SA* spinal anesthesia; *C* control;*O* ondansetron; *T* tramadol; *M* meperidine; *D* doxapram; *G* granisetron; *CL* clonidine; *P* pethidine

In 15 trials, participants were adults. One trial \[[@CR23]\] included children aged 5--12 years. Participants in seven trials \[[@CR10], [@CR12], [@CR13], [@CR18], [@CR19], [@CR23], [@CR24]\] underwent operations under general anesthesia; participants in nine trials \[[@CR11], [@CR14]--[@CR17], [@CR20]--[@CR22], [@CR25]\] were under spinal anesthesia. In 13 trials \[[@CR10], [@CR12], [@CR14]--[@CR23]\] ketamine was compared to placebo; in 4 trials \[[@CR12], [@CR13], [@CR23], [@CR24]\] ketamine was compared to pethidine; in the other 4 trials \[[@CR11], [@CR15], [@CR16], [@CR22]\] ketamine was compared to tramadol. Ketamine was also compared to ondansetron in 4 trials \[[@CR10], [@CR15], [@CR17], [@CR21]\].

The administration time and routes were different among included trials. In 10 trials \[[@CR11], [@CR14]--[@CR17], [@CR20]--[@CR23], [@CR25]\] the intervention drugs were given immediately after induction of anesthesia or intrathecal injection; in five trials \[[@CR10], [@CR12], [@CR18], [@CR19], [@CR24]\] drugs were administrated before completion of the surgical procedure; in one trial \[[@CR13]\] patients received study drugs before wound closure. Study drugs were given as an IV bolus in 14 trials \[[@CR10]--[@CR22], [@CR24]\]; in two trials, patients received the study drugs epidurally \[[@CR25]\] or intramuscularly \[[@CR24]\]. In four trials \[[@CR14], [@CR15], [@CR18], [@CR19]\], patients underwent orthopedic surgery; patients in two studies \[[@CR21], [@CR22]\] underwent abdominal surgery; patients in two studies \[[@CR16], [@CR17]\] underwent cesarean section; patients in two studies \[[@CR20], [@CR25]\] underwent urological surgery; in three trials, participants received ENT surgery \[[@CR10]\], endoscopic sinus surgery \[[@CR12]\], or tonsillectomy surgery \[[@CR23]\].

Regarding measurement of intensity of shivering in a patient, 13 trials \[[@CR10], [@CR13]--[@CR17], [@CR19]--[@CR25]\] utilized a scale with variation points ranging from 0 to 4: 0 = no shivering; 1 = piloerection or peripheral vasoconstriction, but no visible shivering; 2 = muscular activity in only one muscle group; 3 = muscular activity in more than one muscle group, but not generalized; 4 = shivering involving the whole body. One trial \[[@CR12]\] applied a 0--3 scale for evaluating the intensity: 0 = no shivering; 1 = mild fasciculation of face or neck muscles; 2 = visible tremor involving more than one muscle; 3 = gross muscular activity involving the entire body. Two studies \[[@CR11], [@CR18]\] did not assess the intensity of postanesthetic shivering.

Assessment of the risk of bias in the included studies {#Sec8}
------------------------------------------------------

Two authors (Y.Z., A.M.) independently assessed the following domains using the Cochrane 'Risk of bias' tool: Sequence generationAllocation concealmentBlinding of participants, personnelBlinding of outcome assessmentIncomplete outcome dataSelective outcome reportingOther bias

We completed 'Risk of bias' figures for each included study (Fig. [2](#Fig2){ref-type="fig"}). See more details in Appendix. Fig. 2Risk of bias graph and summary

Publication bias {#Sec9}
----------------

Begg's test showed that there was no publication bias for the primary outcome (*p* = 0.055).

### Effects of interventions {#Sec10}

#### Primary outcome {#FPar1}

**Ketamine vs placebo**

The incidence of postanesthetic shivering was compared between ketamine and a placebo in 13 trials including 1166 patients (Fig. [3](#Fig3){ref-type="fig"}). Ketamine has been shown to significantly decrease the incidence of shivering (pooled OR = 0.13; 95% CI: 0.06 to 0.26, *P* \< 0.00001). There was significant and prominent heterogeneity for this outcome (I^2^ = 74%). Begg's test showed that there was no risk of publication bias (*P* = 0.06). A subgroup analysis was performed to explore the evidence-based reason. In subgroup analysis of anesthetic methods, the heterogeneity was 67% in the GA (general anesthesia) group (Fig. [4](#Fig4){ref-type="fig"}). Sensitivity analysis was performed; a trial \[[@CR22]\] was removed which utilized an air forced warmer intraoperatively, which showed a similar result favoring ketamine (pooled OR = 0.18; 95% CI: 0.09 to 0.37) and decreased heterogeneity (I^2^ from 67 to 21%). Ketamine reduced the incidence of postanesthetic shivering in general anesthesia (pooled OR = 0.13; 95% CI: 0.06 to 0.26) and in spinal anesthesia (pooled OR = 0.08; 95% CI: 0.03 to 0.18). (Fig. [5](#Fig5){ref-type="fig"}) shows the subgroup analysis based on the dose of ketamine used in the included trials. Ketamine reduced the incidence of postanesthetic shivering at the dose of 0.25 mg/kg (pooled OR = 0.12; 95% CI: 0.03 to 0.52) and at the dose of 0.5 mg/kg (pooled OR = 0. 14; 95% CI: 0.07 to 0.28). We performed a subgroup analysis based on the type of surgery, as this may influence the incidence of postanesthetic shivering (Fig. [6](#Fig6){ref-type="fig"}). Ketamine significantly lowered the incidence of postanesthetic shivering in patients after orthopedic surgery (pooled OR = 0.32; 95% CI: 0.13 to 0.77). Among patients undergoing abdominal, cesarean section, urological, ENT or endoscopic surgery, ketamine also reduced the incidence of postanesthetic shivering. Fig. 3Forest plots of effects of ketamine on postanesthesia shivering. CI indicates confidence interval Fig. 4Result of subgruop analysis according to different anesthetic methods. CI, confidence interval; GA, genaral anesthesia; SA, spinal anesthesia Fig. 5Result of subgruop analysis according to different doses of ketamine administrated. CI indicates confidence interval Fig. 6Result of subgruop analysis according to different types of surgries. CI indicates confidence interval

**Ketamine vs other pharmacological interventions**

A total of four studies \[[@CR12], [@CR13], [@CR23], [@CR24]\] investigated the effect of ketamine on the prevention of shivering compared with pethidine. The pooled analysis showed a definite difference in favor of pethidine (pooled OR = 4.38; 95% CI: 1.76 to 10.92). No significant difference in postanesthetic shivering was found between ketamine and other pharmacological interventions (Fig. [7](#Fig7){ref-type="fig"}). Fig. 7Forest plots of effects of ketamine on postanesthesia shivering compared with other study drugs. CI indicates confidence interval

### Secondary outcomes {#Sec11}

**Ketamine vs placebo**

Except for the other side effects (hypotension, bradycardia, hallucination), there was no significant difference in the incidence of postoperative nausea and vomiting (PONV) between ketamine and the placebo (pooled RR = 0.72; 95% CI: 0.48 to 1.08) (Table [2](#Tab2){ref-type="table"}). Ketamine reduced the incidence of hypotension and bradycardia compared with the placebo (pooled RR = 0.28; 95% CI: 0.17 to 0.47; pooled RR = 0.18; 95% CI: 0.05 to 0.65). The incidence of hallucination was more significant and prevalent in the patients who received 0.5 mg/kg ketamine (Table [3](#Tab3){ref-type="table"}); there was only one episode of hallucination in patients receiving 0.25 mg/kg. A pooled analysis was not performed because of the lack of uniform sedation score scales in the trials. All of these studies showed that the patients in the ketamine group were more sedated compared to the placebo group. Five trials \[[@CR14], [@CR16], [@CR17], [@CR19], [@CR23]\] reported a significant decrease in core temperature in both the ketamine and placebo groups compared to the baseline temperature of participants. However, it was not significant between groups, at any time point. Three trials \[[@CR20]--[@CR22]\] reported a significant difference in core temperature between ketamine and the placebo; a greater decrease in temperature was found in the placebo group. Table 2Comparisons of incidence of other side effectsSide effcctsNumber of studiesKetaminePlaceboEvents/TotalEvents/TotalOdds Ratio (95% CI)Nausea and vomitting1148/52357/4630.70 \[0.44, 1.12\]Hypotension623/30261/2710.30 \[0.18, 0.49\]Bradycardia23/11211/810.14 \[0.04, 0.52\]Hallucination516/2720/1514.41 \[1.14, 17.07\]Abbreviations: *CI* confidence interval Table 3Episodes of hallucination based on the dose of ketamineStudy IDDose of ketamineKetaminePlaceboEvents/TotalEvents/TotalHonarmand 20080.5 mg/kg3/300/30Han 20100.4 mg/kg2/300/31Norouzi 20110.25 mg/kg1/300/30Norouzi 20110.5 mg/kg4/300/30Ayatollahi 20110.5 mg/kg3/300/30Abdelhalim 20140.5 mg/kg1/300/30

**Ketamine vs other pharmacological interventions**

No significant difference was found in the incidence of PONV between ketamine and pethidine (pooled OR = 0.88; 95% CI: 0.38 to 2.07). Compared to tramadol, the difference in the incidence of PONV and hypotension is not significant (OR = 0.57; 95% CI: 0.18 to 178; OR = 0.90; 95% CI: 0.36 to 2.24). The incidence of PONV was higher in the ketamine group than the ondansetron group (OR = 4.49; 95% CI: 1.24 to 16.21). However, ketamine showed a lower incidence of hypotension compared to ondansetron (OR = 0.09; 95% CI: 0.00 to 3.23). Core temperature changes were reported graphically; there was no significant difference between ketamine and other pharmacological interventions.

**Summary of findings and quality of evidence**

The Summary of findings with GRADE recommendations are shown in Table [4](#Tab4){ref-type="table"}. Table 4Summary of findings with GRADE recommendationsketamine for postoperative shiveringPatient or population: patients with postoperative shiveringSettings: hospitalsIntervention: ketamineOutcomesIllustrative comparative risks^a^ (95% CI)Relative effect (95% CI)No of Participants (studies)Quality of the evidence (GRADE)CommentsAssumed riskCorresponding riskControlKetamineIncidence of shiveringStudy populationOR 0.13 (0.06 to 0.26)1166 (13 studies)⊕ ⊕ ⊝⊝ low^1^468 per 1000103 per 1000 (50 to 186)Moderate500 per 1000115 per 1000 (57 to 206)Nausea and vomittingStudy populationOR 0.7 (0.44 to 1.12)986 (11 studies)⊕ ⊕ ⊝⊝ low^1^123 per 100089 per 1000 (58 to 136)Moderate125 per 100091 per 1000 (59 to 138)HypotensionStudy populationOR 0.3 (0.18 to 0.49)573 (7 studies)⊕⊝⊝⊝ very low^1^225 per 100080 per 1000 (50 to 125)Moderate200 per 100070 per 1000 (43 to 109)BradycardiaStudy populationOR 0.14 (0.04 to 0.52)193 (2 studies)⊕⊝⊝⊝ very low^1^136 per 100022 per 1000 (6 to 76)Moderate165 per 100027 per 1000 (8 to 93)HallucinationStudy populationOR 4.41 (1.14 to 17.07)423 (5 studies)⊕⊝⊝⊝ very low^1^0 per 10000 per 1000 (0 to 0)Moderate0 per 10000 per 1000 (0 to 0)^a^The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)*CI* Confidence interval; *OR* Odds ratio;GRADE Working Group grades of evidenceHigh quality: Further research is very unlikely to change our confidence in the estimate of effectModerate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimateLow quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimateVery low quality: We are very uncertain about the estimate

Discussion {#Sec12}
==========

In the present study, we compared different randomized controlled trials to identify the beneficial aspects of ketamine. We compared the usage of ketamine and its relevance in anaesthetic shivering. In total, 16 studies including 1485 patients were analysed.

Ketamine was first synthesized in the early 1960s as a safe alternative to phencyclidine \[[@CR26]\]. It is a non-competitive -NMDA receptor antagonist with an effect of thermoregulation. Other than being a competitive NMDA receptor antagonist, ketamine also acts as an opioid agonist \[[@CR27]\]. Further, it can cause blockage of amine uptake in the descending inhibitory monoaminergic pain pathways, having a local anaesthetic action and interacting with the muscarinic receptors \[[@CR28]\]. In contrast, even at sub-anaesthetic doses, ketamine might cause a dissociative state, characterised by a sense of detachment from one's physical body and the external world (depersonalization and derealization). Ketamine probably controls shivering by acting on non-shivering thermogenesis \[[@CR29]\]. Ketamine is predominantly utilized as an anaesthetic agent that induces analgesia but for a long time it has been criticized for some of its side effects which include the induction of a psychedelic state causing agitation and hallucinations \[[@CR30]\].

The key findings of our analysis are as follows. Ketamine exposure was relatively better in reducing the occurrence of postanaesthetic shivering compared to placebo. Compared with tramadol and ondansetron, ketamine slightly lowered the incidence of postanaesthetic shivering although not significantly. The effect of ketamine on postanaesthetic shivering remained equally beneficial for both spinal and general types of anaesthesia. A dose of 0.5 mg/kg had an advance effect compared to 0.25 mg/kg on the postanaesthetic shivering rate. The effect remained constant for all types of surgical procedures including orthopaedic surgery, laparotomy, caesarean section, urological, ENT, and endoscopic surgeries. Compared to ketamine, pethidine showed a quicker responsive rate. However, sufficient data was not available in other studies to show any advantage of other pharmacological interventions.

Furthermore, we evaluated the side effects of the anaesthetic drugs and the role of ketamine in preventing or overcoming the effects. Moreover, the efficacy of ketamine was compared with a placebo. The side effects observed in the trials were nausea, vomiting, hypotension, bradycardia, and hallucinations. Ketamine showed a favourable outcome in reducing the incidence rate of hypotension and bradycardia as ketamine causes dose dependent direct stimulation of the CNS which leads to increased sympathetic nervous system stimulation followed by increased systemic blood pressure and heart rate.

However, there was no effect of ketamine in decreasing the incidence rate of nausea and vomiting as compared to placebo. As ketamine is known to have a hallucinogenic effect, it is considered to have a potential role in glutamatergic signalling in psychosis; therefore, the usage of ketamine is suggested to be associated with auditory and verbal hallucinations. In our comparative study, we also found that the rate of occurrence of hallucination episodes was much higher in patients receiving a ketamine dose of 0.5 mg/kg compared to a lower dose of 0.25 mg/kg. The hallucinogenic effect of ketamine was evident when compared with the placebo drugs, for which there was no incidence of hallucinations reported in any of the trials. Ketamine can cause sedation in postoperative patients and deep sedation is considered to be a severe adverse event. However, for those experiencing shivering, mild sedation may prevent them from hurting themselves. In our study, we paid special attention to the sedation score of patients, although pooled analysis was not conducted because of various sedation scales. We found that mild to moderate sedation was more commonly seen in patients receiving different doses of ketamine.

Besides various pharmacological interventions above, we noticed that active warming for elective caesarean delivery reduced the incidence of postoperative shivering and provided more stable perioperative temperature change ^\[31\]^. Accumulating evidence has shown that the active warming method including electric heating, water-circulating garments, forced-air, and radiant heating is effective in preventing post-anaesthetic shivering. The current American Society of Anesthesiologists Task Force on Postanesthetic Care guidelines recommend forced-air warming as a common method to reduce shivering in the perioperative setting ^\[32\]^. Future research should focus on combinations of pharmacological interventions with non-pharmacological methods to better solve this problem.

The major limitation of our study is that we could not study the hemodynamical changes related to ketamine usage as there were no standard criteria being followed by the trials causing irrelevancy and uneven data for comparing and evaluating precise outcomes in this regard. Second, the sample size of included trials was relatively small which may decrease generalisability of our conclusions. Third, the evidence level for our outcomes was low or very low. However, we believe that our study is of value because it provided clear evidence of the benefit of prophylactic ketamine intervention for preventing post-anaesthetic shivering which may be helpful in clinical practice.

Conclusion {#Sec13}
==========

In this meta-analysis, we assessed various aspects of ketamine usage in controlling post-anaesthetic shivering. We found that ketamine reduced the incidence rate of shivering compared to the placebo. Although it is beneficial, it did not show any superiority over other pharmacological interventions. Ketamine is of clinical value, but further studies should be performed on a wider scale to determine more emphasized results. Furthermore, larger clinical trials investigating the combination of different anti-shivering regimens are warranted.

CNS

:   Central nervous system

ECG

:   Electrocardiography

ENT

:   Ear-nose-throat

NMDA

:   N-methy-D-aspartate

PONV

:   Postoperative nausea and vomiting

PRISMA

:   Reporting Items for Systematic Reviews and Meta-Analysis

SpO2

:   Oxygen saturation
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